Navigation Links
Proteolix's Carfilzomib Receives Orphan Drug Designation for Treatment of Multiple Myeloma
Date:4/2/2008

SOUTH SAN FRANCISCO, Calif., April 2, 2008 /PRNewswire/ -- Proteolix, Inc., a clinical-stage company engaged in the development of novel pharmaceutical therapies for the treatment of cancer and immunological conditions, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to carfilzomib, a selective blocker of proteasome activity for the treatment of multiple myeloma. The orphan drug designation encompasses all subsets of multiple myeloma and Waldenstrom's macroglobulinemia.

"I am very pleased by our receipt of this designation for carfilzomib," said Susan Molineaux, Ph.D., the Company's President and CEO. "To date we have been encouraged by carfilzomib's early-stage clinical results in multiple myeloma, and we continue to believe it has the potential to offer cancer patients a new and effective treatment for their disease."

The Orphan Drug Act of 1983 allows the FDA to grant orphan drug status to novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the U.S. According to the SEER Database of the National Cancer Institute (2004), the U.S. prevalence of multiple myeloma was 53,712 patients. The Orphan Drug Act provides the drug developer with several financial benefits and incentives related to the orphan drug, including tax credits for clinical research costs, ability to apply for annual grant funding, clinical research trial design assistance, waiver of Prescription Drug User Fee Act (PDUFA) filing fees, and a seven-year period of U.S. marketing exclusivity if the drug is the first of its type approved for the specified indication.

About Multiple Myeloma

Multiple myeloma is cancer of the plasma cell. It begins in the bone marrow, where blood cells are made. The plasma cell is a type of white blood cell that fights infections by making antibodies. Cancerous plasma cells, also called myeloma cells, divide and grow out of control, build
'/>"/>

SOURCE Proteolix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Vermillion Meets Minimum Bid Price and Receives NASDAQ Staff Determination Letter for Minimum Market Capitalization
3. Pharmasset Receives $10 Million of Working Capital
4. Memory Pharmaceuticals Receives Audit Opinion Containing Going Concern Qualification
5. Actavis Receives Approval of Generic Wellbutrin SR(R) and Zyban(R) Tablets in the U.S.
6. Seneca Valley High School Student Receives Science Award From MedImmune
7. Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia
8. Medarex Receives Milestone Payment for Submission of Regulatory Application Requesting Approval of Golimumab (CNTO 148) in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
9. Oregon Health Care Quality Corporation Receives Important Designation from U.S. Department of Health and Human Services
10. AdvanDx Receives Frost & Sullivans Rapid In-Vitro Diagnostic Technology Innovation of the Year Award
11. Axial Biotech Meets Major Scientific Milestones; Receives $6 Million Tranche of Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Denver, CO (PRWEB) July 29, 2014 ... and soiled linen collection and transport solutions for hospitals, ... Society for Healthcare Engineering (ASHE) Annual Conference & Technical ... TransVac will present its technology for making hospitals cleaner, ... operational costs over the hospital’s life cycle. Staff ...
(Date:7/29/2014)... July 29, 2014 Genera ... feedstock supply innovation and supply chain advancements, has ... management systems, Energy Grange™ and Supply ASSURE™. ... and in-the-field testing aimed at consolidating and simplifying ... to landowners, farmers and feedstock end users. , ...
(Date:7/29/2014)... Quorum Review IRB, the industry leader ... by the International Association of Six Sigma ... Deployment Program. The citation recognizes robust organizational enhancements ... Lean Six Sigma program was evaluated by IASSC ... designation is a public statement of excellence and ...
(Date:7/29/2014)... 29, 2014 The first product launch ... generation approach to robotics. What sets Droidles completely apart ... technology that allows them to communicate, share code with ... the internet. , “The invention is the system,” said ... Droidles a life of their own, both physically and ...
Breaking Biology Technology:TransVac Presents Cost Saving Technology at ASHE Conference for Keeping Hospitals Cleaner 2Genera Energy Introduces Proprietary Feedstock Management Systems 2Genera Energy Introduces Proprietary Feedstock Management Systems 3Genera Energy Introduces Proprietary Feedstock Management Systems 4Quorum Review IRB Accredited by IASSC for Lean Six Sigma Deployment Program 2Quorum Review IRB Accredited by IASSC for Lean Six Sigma Deployment Program 3Droidles, the Social Network of Robots and Open Source Platform for the Internet of Things, Launches for Crowd Funding on IndieGoGo.com 2
... 2011 Landauer, Inc. (NYSE: LDR ... monitoring and the leading domestic provider of outsourced medical physics ... quarter ended March 31, 2011.   Fiscal 2011 ... to $32.3 million on contribution from Medical Physics segment and ...
... N.J., May 3, 2011 BioNeutral Group, Inc. ... today announced that it has signed on to ... disinfectant technology to the infection control professionals attending ... in Infection Control and Epidemiology) ( www.apic.org ). ...
... Inc. (Nasdaq: VVUS ), a biopharmaceutical company dedicated to ... financial results for the first quarter ended March 31, 2011. ... 2011, VIVUS reported a net loss of $9.9 million or $0.12 ... or $0.23 per share for the first quarter of 2010. The ...
Cached Biology Technology:Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 2Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 3Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 4Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 5Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 6Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 7Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 8Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 9Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 10Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 11Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 12BioNeutral to Premier its EPA-Approved Ygiene® 206 Hospital-Grade Disinfectant at the Annual 2011 APIC Conference, While Community Health of South Florida Begins Product Review 2BioNeutral to Premier its EPA-Approved Ygiene® 206 Hospital-Grade Disinfectant at the Annual 2011 APIC Conference, While Community Health of South Florida Begins Product Review 3BioNeutral to Premier its EPA-Approved Ygiene® 206 Hospital-Grade Disinfectant at the Annual 2011 APIC Conference, While Community Health of South Florida Begins Product Review 4VIVUS Reports First Quarter 2011 Financial Results 2VIVUS Reports First Quarter 2011 Financial Results 3VIVUS Reports First Quarter 2011 Financial Results 4VIVUS Reports First Quarter 2011 Financial Results 5
(Date:7/29/2014)... some good news for parents of preterm babies latest ... by the time they become teenagers, the brains of many ... at term. , A study conducted by the University,s ... the preterm child experiences no brain injury in early life, ... good as their term-born peers. , However, the results of ...
(Date:7/29/2014)... it affects 1 in 100,000 people characterized by ... its cause remains unknown, a new study by a team ... Bonn in Germany and other European institutions confirms for the ... published on 6 July in Nature Genetics , is ... we swallow, a sphincter in the lower esophagus opens, allowing ...
(Date:7/29/2014)... A new study from UC San Francisco is the ... stressors accumulate overtime and accelerate cellular aging, these negative ... exercising and sleeping well. , "The study participants ... telomere shortening than the ones who didn,t maintain healthy ... said lead author Eli Puterman, PhD, assistant professor in ...
Breaking Biology News(10 mins):Preterm children's brains can catch up years later 2Mysterious esophagus disease is autoimmune after all 2Healthy lifestyle may buffer against stress-related cell aging, study says 2
... breathing problems after birth, and rare, inherited DNA differences may ... Medicine in St. Louis. The study is the first ... associated with a significant number of cases of respiratory distress ... RDS is the most common respiratory problem in newborns and ...
... Putnam Valley, NY. (Nov. 27, 2012) A ... Cell Transplantation (21:8), now freely available on-line ... mesenchymal cells derived from skeletal muscle (SM-MSCs) or ... muscle (myocardium) of separate groups of laboratory rats ...
... scientists from the University of Navarra and the Catalan Association ... Maestrazgo caves in Teruel, Spain. Their description has been published ... to one of the most ancient animal species on the ... a region of the Iberian Range where fauna has not ...
Cached Biology News:Gene linked to respiratory distress in babies 2Gene linked to respiratory distress in babies 3Study suggests different organ-derived stem cell injections improve heart function 2Three new arthropod species have been found in the Maestrazgo Caves in Teruel 2
... For the ultimate in utility and ... to meet the needs of the researcher. ... interior dimensions or as sheet material that ... enclosures. These isolators are autoclavable and non-cytotoxic ...
2,4-Dinitrophenyl hapten is conjugated to Human Serum Albumin (HSA) protein through lysine....
IC50: 3 ng/ml · Limit of detection: 0.5 ng/ml...
Antibodies were affinity purified using epitopes specific to PPP1CC immobilized on solid support....
Biology Products: